AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04432428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet
Description: all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil
Study NCT01815684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral
Study NCT00263939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homing in on Health
Description: A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
Study NCT00585650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
Study NCT00585650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injections
Description: Placebo injections twice weekly for 12 weeks.
Study NCT00604383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruboxistaurin
Description: 32-mg tablet, orally, daily, up to 42 months
Study NCT01815684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral
Study NCT03114969 — intervention group
Intervention type: DEVICE
Intervention: Relvar ELLIPTA
Description: ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
Study NCT03114969 — intervention group
Intervention type: DEVICE
Intervention: Symbicort TURBUHALER
Description: TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
Study NCT03114969 — intervention group
Intervention type: DEVICE
Intervention: Seretide DISKUS
Description: DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
Study NCT03114969 — intervention group
Intervention type: DEVICE
Intervention: Spiriva HANDIHALER
Description: HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
Study NCT03114969 — intervention group
Intervention type: DEVICE
Intervention: BREEZHALER
Description: BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
Study NCT03114969 — intervention group
Intervention type: DEVICE
Intervention: Incruse ELLIPTA
Description: ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
Study NCT03114969 — intervention group
Intervention type: DEVICE
Intervention: Anoro ELLIPTA
Description: ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
Study NCT00519623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PassPort(R) Transdermal Insulin Delivery System
Description: The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
Study NCT01824602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1800 mg
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Study NCT01824602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Study NCT01824602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 600 mg
Description: Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
Study NCT00604383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tablet, orally, daily, up to 42 months
Study NCT00997126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
Study NCT00997126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
Study NCT01824602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pills
Study NCT05042245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornithine aspartate granule
Description: Ornithine aspartate granules in the experimental arm.
Study NCT05042245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin capsule
Description: Silymarin capsules in the active comparator arm.
Study NCT05042245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin capsule simulant
Description: Silymarin capsule simulant in the experimental arm.
Study NCT03769896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, corn starch, daily basis
Study NCT04354493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myo-electric Gaming Interface
Description: Non-significant risk, video game controller which maps myo-electric control signals to button presses.
Study NCT04548635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-PAT
Description: Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
Study NCT03199872 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV001V
Description: Sc injection
Study NCT06084494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: analytical determination and interpretation of heat stress using calculation of the Predicted Heat Strain and Wet Bulb Globe Temperature
Description: The temperature inside the climatic chamber was set at 40 C and 31 C at a relative humidity of 20 % and 70 % respectively to count for a WBGT level of 28 C. The subject does walk at 5 km/h and jog at 8 km/h under these conditions for up to 70 minutes. The test includes the measurement of the height and weight of the subjects, heart rate, oxygen consumption, body weight loss (sweat evaporation), skin temperature, and core body temperature under hot environmental conditions. Subjective responses will also be recorded. WBGT was recorded after every ten minutes by heat stress meter and Bruel Kjaer.
Study NCT01312844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine
Description: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
Study NCT04270786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early de-escalation
Description: In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.
Study NCT04270786 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard
Description: In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
Study NCT01312844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
Study NCT02476994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinolipid
Study NCT02476994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Standard-of-Care Soybean Oil-Based Lipid Emulsion
Study NCT02256683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
Study NCT02256683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
Study NCT03037554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleepwear with Lateralized Thermal Characteristics
Description: Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.
Study NCT03037554 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Lateralized Sleepwear
Description: Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
Study NCT02907983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block Injection with Bupivicaine
Description: A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Study NCT02907983 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline injection
Description: A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Study NCT04510545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endobrain, Computer Aided Diagnosis (CAD)
Description: Artificial intelligence
Study NCT01621945 — intervention group
Intervention type: BIOLOGICAL
Intervention: MenBvac
Description: Blood test
Study NCT03676764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
Study NCT01769365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-day quadruple therapy
Description: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
Study NCT01769365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy
Description: pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
Study NCT01769365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7-day standard triple therapy
Description: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
Study NCT01641783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle Albumin-Bound paclitaxel
Description: nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
Study NCT00520442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Study NCT00520442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetamin w codeine
Study NCT02372084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osilodrostat
Study NCT01272895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Intervention (GENOUS stent)
Description: GENOUS stent (Coronary Intervention)
Study NCT02271542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
Study NCT03491683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-5401
Description: INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
Study NCT03491683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012
Description: INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
Study NCT03491683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
Study NCT03491683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
Study NCT03491683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).
Study NCT00704080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
Study NCT00704080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
Study NCT02328469 — intervention group
Intervention type: DRUG
Intervention: symptomatic therapy
Description: patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
Study NCT03142750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastrostomy tube dressing
Description: Two types of dressings to secure gastrostomy tube in children
Study NCT02911467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyruvate (13C)
Description: Pyruvate injection followed by an MRI scan.
Study NCT02911467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan following the Pyruvate injection
Study NCT01870570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference Glucose
Study NCT01870570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product A: Corn Flakes
Study NCT03676764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
Study NCT03676764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
Study NCT03040648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DSA
Description: DSA was used for detection of intravascular injection
Study NCT03040648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RTF
Description: RTF was used for detection of intravascular injection
Study NCT01068821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gel pad
Description: A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
Study NCT01068821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg crate foam mattress
Description: An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
Study NCT03825328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
Study NCT03825328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: a combination preparation of tegafur, gimeracil, and oteracil potassium
Study NCT03825328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
Study NCT03825328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a synthetic pyrimidine nucleoside prodrug-a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
Study NCT01870570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product B: Ginger Bread
Study NCT01870570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product C:Sandwiched Breakfast Biscuit
Study NCT02505347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No splint
Description: Can move arm as tolerated with no restrictions on mobility
Study NCT01870570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Product D: Crackers Nature
Study NCT02505347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint
Description: Wear splint for 6 weeks, only to remove for rehab and personal care
Study NCT05042245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ornithine aspartate granule simulant
Description: Ornithine aspartate granule simulant in the active comparator arm.
Study NCT03138564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIRIT
Description: SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record.
Study NCT03138564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Condition
Description: As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
Study NCT02279316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vi-De 3
Description: All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.